Jump to content

GlaxoSmithKline (GSK) share price: Q2 earnings preview


Recommended Posts

GlaxoSmithKline Q2 revenue is expected to show revenue growth from newer drugs partially offset by increased generic competition in older drugs.

TraderSource: Bloomberg
 
 Shaun Murison | Senior Market Analyst, Johannesburg | Publication date: Tuesday 27 July 2021 

When is GlaxoSmithKline earnings date?

The GlaxoSmithKline (GSK) earnings release date is scheduled for the 28 July 2021. The scheduled results will cover the groups second quarter and half-year earnings.

 

GSK results preview: What does the street expect?

While GlaxoSmithKline (in partnership with Sanofi Pasteur) look to stage three trials of their Covid-19 vaccine, the company has not yet released a vaccine to market. The global rollout of Covid-19 vaccines (by competitors) looks to have disrupted the course of other vaccine programmes in key markets such as the US and the UK for GSK.

Revenue for second quarter (Q2) 2021 is expected to be bolstered by sales of newer drugs in the respiratory and HIV segments, with a partial offset from older drugs which are finding increased competition through generic offerings.

In terms of the upcoming results, a mean of analyst estimates compiled by Refinitiv data arrive at the following:

How to trade the GlaxoSmithKline results

 

GlaxoSmithKline chartSource: Refinitiv

 

A Refinitiv poll of analyst ratings arrive have a long term consensus rating of ‘buy’ for GlaxoSmithKline with a target price $47.87.

GlaxoSmithKline (ADR) share price: technical analysis

 

GlaxoSmithKline (ADR) chartSource: IG

The share price of GlaxoSmithKline continues to trade in an uptrend which has been in place since the beginning of March 2021. The price has however started to correct from near term highs.

The correction sees the price now testing support at the 38.85 level. Traders looking for long entry might prefer to see a bullish price reversal around current levels accompanied by a sharper move out of oversold territory by the Stochastic oscillator. In this scenario, the recent high at 40.55 would become the initial resistance target, while a close below 38.35 could be used as a stop loss consideration for the trade.

However should a bullish price reversal not manifest and we see the price move to close below both the 38.85 and 38.35 support levels, this could instead be a suggestion that the uptrend has failed and perhaps a new downtrend for the share price is forming.

In Summary

  • GSK reports Q2 2021 results on the 28 July
  • Q2 revenue of $10.433 billion (+10.27% YoY) is expected
  • Q2 EBITDA of $2.855 billion (-8.91% YoY) are expected
  • EPS $0.51 (+10.87% YoY) in the Q2 are expected
  • The average long term broker rating for GSK is a ‘buy’
  • The share price of GSK is testing support as it finds itself in a short-term correction of a longer-term uptrend
Link to comment

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
  • General Statistics

    • Total Topics
      21,157
    • Total Posts
      90,663
    • Total Members
      41,266
    • Most Online
      7,522
      10/06/21 10:53

    Newest Member
    BMadoff
    Joined 26/01/23 23:07
  • Posts

    • Content: US Bond Yields, Dollar DXY, US Gold, Silver, Copper, Lithium, Uranium, Nickel, Crude Oil, Natural Gas Commodities Market Summary: Bond yields and US DXY lower, commodities higher Trading Strategies: Hold Long Lithium, Uranium, Gold, Nickel. Video Chapters 00:00  US Gov Bonds 10 Yr Yields 01:22 US Dollar Index DXY  03:48 US Spot Gold GDX ABX NCM 17:02 US Spot Silver 18:20 US Copper / Lithium / Uranium / Nickel (China, Emerging Markets, stocks) 37:48 Crude Oil, Sector XLE / XOM   44:52 Natural Gas 54:07 TRIAL Buy 1 Month Get 3 Months Analyst Peter Mathers TradingLounge™ Australian Financial Services Licence - AFSL 317817 Source: tradinglounge com      
    • Tesla reported earnings of $1.19 per share after the US market close yesterday - four cents higher than analyst expectations. While revenue was at a record high it came in just short of the bullish expectations at $24.32 billion.  Jeremy Naylor | Writer, London | Publication date: Thursday 26 January 2023 Tesla shares up on earnings Tesla shares rose 8% yesterday in extended trade on the IG platform, up a further notch higher by a margin of 5% on from what we saw during full trading yesterday. And this is as a result of earnings out late last night. Let's take a look at the figures. The electric carmaker reported earnings of $1.19 per share after the US markets closed. That's $0.04 higher than analysts expected. Revenue was just short of expectations at $24.32 billion. These are record numbers, according to the company. In a call to investors, CEO Elon Musk said he expected a pretty difficult recession this year for the US economy. But demand for Tesla vehicles, he says, will be good, despite a probable contraction in the automotive market as a whole, adding that absent external disruptions, 2023 deliveries could hit two million vehicles. Share price chart Overall, let's take a look at the share price chart. This stock is now up 51% from the lows that we had back in January and I'm talking January this year. So it's just shy of three weeks. That is a whopping increase. But you've got to bear in mind, the stock has fallen substantially from the record highs we saw back on the 4th of November 2021. We've lost 75.6% of overall value in Tesla. So this uptick here when you're looking at this sort of improvement from those lows, it is an incredible move in terms of percentages, but it's risen from $103 up to $152. So that's what we're opening this morning at 9:00 UK time, extended trade after that big gain yesterday on those numbers coming through from Tesla.
×
×
  • Create New...